

To,

Date: 26th May, 2026

The Manager
BSE Limited
P. J. Towers, Dalal Street
Mumbai-400001
(BSE Scrip Code: 544742)

The Manager,
NSE Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.
(NSE Symbol: SAIPARENT)

Dear Sir/Madam,

Unit: Sai Parenterals Limited

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Copy of Presentation made for Analysts/Investors on Financial Results.

In compliance with the provisions of Regulation 30 read with Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of presentation made for Analysts/Investors on Financial Results of the Company for the quarter and year ended March 31, 2026.

Request you to kindly take the same on record.

Thanking you,

**Yours faithfully,
For Sai Parenterals Limited**

**Mr. Anil Kumar Karusala
Managing Director
(DIN- 01866646)**

INVESTOR PRESENTATION

Q4 & FY26

MAY 2026

This presentation and the accompanying slides (the "Presentation"), which have been prepared SAI Parenteral's Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

01

QUARTERLY
REVIEW



Financial highlights


- Q4FY26 consolidated revenue at ₹198 crore; EBITDA at ₹29 crore, reflecting first full-quarter consolidation of Noumed
- FY26 consolidated revenue at ₹381 crore, establishing a stronger platform for future growth
- Standalone FY26 revenue, EBITDA and PAT grew 31%, 23% and 64%, respectively, driven by strong CDMO momentum
- CDMO revenue surged over 250% YoY, supported by deeper engagement with our customers

Operational highlights

- Expanded portfolio by 93 dossiers in FY26, including 88 regulated/emerging market filings and 5 TGA Australia dossiers through Noumed
- 67 dossiers under development, providing strong visibility for export-led growth in FY27 and beyond
- Secured long-term CDMO contracts, strengthening revenue visibility and growth outlook
- Enhanced global market access through expansion in Australia and New Zealand

FY26 standalone financial highlights

REVENUE (₹ CRORE)



₹162 crore

Revenue from operations

▲ 31%

EBITDA

	FY25	FY26
EBITDA (₹ Cr)	27	33
EBITDA margin (%)	22%	20%

₹33 crore

EBITDA

▲ 23%

PAT

	FY25	FY26
PAT (₹ Cr)	10	17
PAT margin (%)	8%	10%

₹17 crore


PAT

▲ 64%

▲ YoY

FY26 consolidated* financial highlights

REVENUE (₹ CRORE)



₹381 crore
Revenue from operations

EBITDA

	Q4FY26	FY26
EBITDA (₹ Cr)	29	47
Margin (%)	24%	12%

₹47 crore
EBITDA

PAT

	Q4FY26	FY26
PAT (₹ Cr)	13	14
Margin (%)	9%	4%

₹14 crore
PAT

* Consolidated financials include wholly owned subsidiaries, Revat Laboratories Private Limited and Sai Parenterals Pte. Ltd. (Singapore), a 74.6% stake in Noumed Pharmaceuticals Pty Limited (Australia), and its wholly owned subsidiary, Noumed Pharmaceuticals Limited (New Zealand). The acquisition of Noumed Pharmaceuticals Pty Limited was completed on November 12, 2025, and its financials have been consolidated from the acquisition date.

02

COMPANY OVERVIEW



SAI Parenteral's Limited is a diversified global pharmaceutical formulations company with capabilities in research, development and manufacturing

Diversified business model

- Revenue mix is diversified across **branded generics formulations and CDMO products and services**
- Comprehensive portfolio of **302 complex products**, covering all critical therapeutic areas
- Exclusive long term supply business agreements signed with customers in **Australia, New Zealand and Philippines**
- **Comprehensive broad dosage forms:** Manufacturing all dosage forms Liquid and dry powder injectables, tablets, capsules, liquid orals, sprays, ointments and dry syrups

Focus on Global CDMO platform

- **Preferred CDMO partner for customers** in the regulated and semi-regulated markets
- **Acquisition of 74.60% in Australia-based Noumed Pharmaceuticals Pty Limited** strengthens the CDMO platform
- **599 approved product registrations** with regulated markets in product portfolio (**456** approved in TGA-Australia; **143** approvals in other countries)



Injectable capabilities

- Focus on **critical care injectables** and **penicillin-based therapies**
- Operating 3 Sterile injectable facilities in Hyderabad (Unit I, II and IV)
- Current delivery systems includes dry powder injections, pre-filled syringes, liquid ampoules, and liquid vials
- **Capex Infusion to add lyophilized and cartridge-based dosage forms**

Regulated market approved facilities

- **Capex infusion** at injectable Units I and II for **EU-GMP upgradation** and **capacity expansion**
- **TGA, Australia approved** manufacturing facility in Hyderabad (Unit III)
- **PIC/S approved** Cephalosporin manufacturing facility (Unit IV) in Hyderabad and in process of Upgrading to EU GMP approval
- Under construction **manufacturing facility** for tablets, liquid orals and nasal sprays in **Adelaide, Australia**; Facility remains on track for completion in Q4FY27



Noumed, with presence in Australia and New Zealand, adds scale, synergy and access to global markets

- **Noumed has exclusive long-term supply agreements** with Australian pharmacy chains, enabling revenue visibility and expansion in **growing Australian CDMO market**
 - Australian CDMO market valued at ~\$2 billion in 2024 with expected to grow at ~11.2% CAGR
- Access to **New Zealand market**, enables both prescription (“Rx”) and OTC products
 - New Zealand CDMO market valued at \$0.56 billion in 2025, expected to grow at ~17.3% CAGR

R&D capabilities




- Identification, development and manufacturing of **cost-effective generic formulations** across therapeutic areas and dosage forms
- Our **dedicated R&D subsidiary, SP Analytics**, will enhance our **FR&D capabilities**, support the **introduction of new products** and **accelerate** the filing of regulatory dossiers
- **Infusion of ₹18 crore** Capex for an **upcoming R&D center** under SP Analytics; Plan to expand R&D headcount by 20 personnel
- **Upcoming R&D center in India** to drive new product launches **in export markets**
- SP Analytics **targeted pipeline strategy** focused on molecules with **patent expiries over the next three years**



Source: Marketysers Report

* Image for Noumed's Manufacturing Facility is used for illustrative purposes only

SPL + Noumed = Platform for growth

	SPL	NOUMED	SYNERGIES
Commercial 	<ul style="list-style-type: none"> • Proven track record in manufacturing • Fast-growing exports and CDMO business • Long term customer agreements in regulatory markets 	<ul style="list-style-type: none"> • Strong presence in Australian market; Exclusive long-term supply agreements with Australian pharmacy chains • Strong presence in New Zealand market, offering both prescription ("Rx") and OTC products 	<ul style="list-style-type: none"> • Supports expansion of SPL's global CDMO business into regulated and semi-regulated markets
Research & Development 	<ul style="list-style-type: none"> • Dedicated R&D subsidiary - SP Analytics • 55 dossiers developed in-house* • Upcoming R&D center 	<ul style="list-style-type: none"> • 451 product registrations approved with TGA-Australia* 	<ul style="list-style-type: none"> • New dedicated R&D center to drive new product launches in both Australia and New Zealand markets • Product registrations/dossiers to be leveraged for Australia, New Zealand, SE Asia, Middle East, Latin America and other regulated and semi-regulated markets
Infrastructure 	<ul style="list-style-type: none"> • Strategically located and regulatory-approved manufacturing facilities in Hyderabad and Ongole^ 	<ul style="list-style-type: none"> • Under construction TGA-approved manufacturing facility for tablets, liquid orals and nasal sprays in Adelaide, Australia; Facility on track for completion in Q4FY27 	<ul style="list-style-type: none"> • Leverage combined manufacturing capabilities to expand into Australian and New Zealand CDMO market

* At the time of acquisition

^ Ongole facility operated through our wholly owned subsidiary, Revat Laboratories Private Limited

Overview

To meet the growing demand from existing and new customers for specialized products, the Company is actively expanding and upgrading its facilities:

Manufacturing Facility	Pre-expansion installed capacity (In Mn units)	Post-expansion installed capacity (In Mn units)	Pre-upgradation accreditations	Post-upgradation accreditations	Capex	Expected date of completion
Unit I (Injectables)	42	78	GMP	EU-GMP, WHO-GMP, PIC/S	₹111 crore	January-2027
Unit II (Injectables)	15	21	WHO-GMP	EU-GMP, WHO-GMP, PIC/S		January-2027
Unit III (General Oral Dosage Forms)	240	451	TGA-Australia, WHO-GMP, PIC/S	TGA-Australia, WHO-GMP, PIC/S		October-2026
Unit IV (Cephalosporin Oral Dosage Forms and Injectables)	293	293	WHO-GMP, PIC/S	EU-GMP, WHO-GMP, PIC/S		January-2027
Dedicated R&D facility	Enhance our formulation development capabilities , support the introduction of new products and further accelerate the preparation and filing of regulatory dossiers				₹18 crore	July-2027
Noumed	Factory is under development; AUD 20 million grant has already been disbursed by the Australian Government for this project				AUD 53 million	Q4FY27

Note: Capacity working is based on a single shift of 8 hours per day for 300 working days in a year. Based on demand conditions, units can be operated in two shifts.

Our journey so far

- Incorporation of Revat Laboratories Pvt Ltd by current promoters
- SAI Parenteral's acquisition of 100% Equity by current promoters
- Acquired PICS Approved Cephalosporin Plant (Unit IV)
- Acquired TGA approved Australia Plant (Unit III)
- Acquired Revat Laboratories Pvt Ltd as a wholly owned subsidiary
- Completed IPO in March 2026 with a primary fund raise of ₹ 285 crore
- Listed on April 02, 2026, on BSE and NSE

1988	2001	2016	2021	2022	2023	2025	2026
------	------	------	------	------	------	------	------

- Incorporation of Sai Parenteral's Pvt Ltd
- Introduction of Prefilled technology in Unit-I
- Achieved a turnover of ₹100 crore
- Set up of Sai Parenterals Pte. Limited in Singapore
- Acquired Australian-based Noumed Pharmaceuticals Pty Limited
- Acquired New-Zealand based Noumed Pharmaceuticals Ltd
- Filed 45 product registrations with FDA, Philippines



* Image for Noumed's Manufacturing Facility is used for illustrative purposes only

03

OUR
STRENGTHS



Diversified branded generic formulations player with an established track record

Since 2016, SAI has grown its revenue and diversified across business verticals, geographical markets, and product

Business model

- Indian business focused on **branded generic formulations**
- **Exports** of branded generic formulations **and CDMO** have grown rapidly post the acquisition of two regulatory approved facilities in Hyderabad
- Noumed's Australia and New Zealand businesses **strengthens CDMO capabilities**



Products

- Manufacturing capabilities across **various dosage forms**
- Focus on **value-added and differentiated dosage forms**
- Noumed's Australia and New Zealand businesses adds to **OTC and Rx** segments









Markets

- Exports covering various geographies across **regulated and semi-regulated markets**
- Serving **multinational pharmaceutical companies** through CDMO partnerships
- **Export revenue** benefits from long term supply agreements



Strategically located & globally accredited manufacturing facilities

Particulars	SAI Unit I	SAI Unit II	SAI Unit III	SAI Unit IV	Revat	Noumed*
Plant location	Jeedimetla, Telangana 	Jeedimetla, Telangana 	Bhongir, Telangana 	Bollaram, Telangana 	Ongole, Andhra Pradesh 	Adelaide, Australia 
Key certifications	GMP (To be upgraded to EU-GMP)	WHO-GMP (To be upgraded to EU-GMP)	TGA – Australia, WHO-GMP, PICS	PICS, WHO-GMP (To be upgraded to EU-GMP)	GMP	The factory is on track for completion by Q4FY27
Installed capacity	42 million units	15 million units	240 million units	293 million units	570 million units	
Key dosage forms manufactured	Liquid injections, sterile non-beta lactam dry powder injections and pre-filled syringes	Sterile penicillin dry powder injections	General dosage forms tablets, capsules, liquid orals, ointments, lotions and sprays	Cephalosporin tablets, capsules and dry syrups	General dosage forms tablets, capsules, liquid orals	Tablets, liquid orals and nasal sprays

* Image for Noumed's Manufacturing Facility is used for illustrative purposes only

Track record of value-accretive acquisitions

Name of entity	Fiscal year of acquisition	Consideration (in ₹ Cr)	Acquisition rationale
Unit III – TGA Australia approved facility, Bhongir, Hyderabad	2022	24	To expand footprint in regulated markets and enhance manufacturing capacity*
Unit IV – PICs approved facility, Bollaram, Hyderabad	2023	11	To strengthen capability in manufacturing oral dosage forms*
Revat Laboratories Private Limited, Ongole (100%)	2024	28	To expand in domestic branded generics formulations presence through a dedicated oral solids facility^
Australia based Noumed Pharmaceuticals Pty Ltd (including its New-Zealand based subsidiary, Noumed Pharmaceuticals Pvt Ltd)	2025	129	Strengthening our export footprint, expanding our presence in regulated markets, and diversifying our product and revenue base



* Units III and IV were acquired as assets and did not generate any revenue prior to acquisition

^ Revat Laboratories was founded by the current promoters and subsequently became a wholly owned subsidiary of the Company

Note: Image used for Noumed's Manufacturing Facility is used for illustrative purposes only

Focus on CDMO platform



Scale-up of CDMO business post acquisition of two regulatory approved plants – expanding through CDMO contracts across regulated and semi-regulated markets

- Australia-based Noumed Pharmaceuticals Pty Limited strengthens our CDMO platform
- New dedicated R&D center to drive new product launches and CDMO business in both Australia and New Zealand market
- SP Analytics will enhance our formulation development capabilities, support the introduction of new products and further accelerate the preparation and filing of regulatory dossiers



Intellectual Property portfolio supporting our CDMO operations

- 506 product registrations in regulatory markets
- 67 product dossiers in development pipeline, target to be completed by FY27
- New dedicated R&D Centre to drive enhanced focus on product filings in speciality and complex pharmaceutical products



Growing customer base across regulated markets by entering into long-term CDMO contracts



SAI is an end-to-end CDMO player with expanding global reach and technical capabilities

SAI's dossier depth, regulatory access, and manufacturing scale position CDMO as a key growth engine



Experienced Promoters and Senior Management

Exceptional management team with more than three decades of experience in the pharmaceutical industry



Anil KK

Managing Director
Sai Parenteral's Limited

Anil KK holds over 31 years' experience in the pharmaceutical industry, with extensive expertise in pharmaceutical manufacturing and commercial operations.

Anil KK provides strategic direction, oversees day-to-day operations, and plays a critical role in driving commercial growth, formulating corporate strategy, and spearheading business expansion initiatives.



Vijitha Gorrepati

Whole-time Director
Sai Parenteral's Limited

Vijitha holds over 14 years' experience in the pharmaceutical industry, with proven capabilities across procurement, technical operations, and quality-driven manufacturing environments.

Vijitha has been instrumental in managing procurement and technical operations, ensuring operational efficiency, supply chain robustness, and strict adherence to quality standards.



Mark Thulborne

Managing Director
Noumed Pharmaceuticals Pty Limited

The senior leadership team, Mark Thulborne, Jo-maree Delac held senior roles at global and regional pharmaceutical companies, including Orion (now Perrigo), API (now part of Wesfarmers), EBOS, and Medreich. Noumed's commercial, operations, quality, and finance heads are based in Australia and New Zealand, providing local leadership aligned with global execution standards.



Jo-Maree Delac

Director
Noumed Pharmaceuticals Pty Limited

Experienced Promoters and Senior Management



D B Venkoji Prakash
Chief Executive Officer
Sai Parenteral's Limited

D B Venkoji Prakash holds over 15 years of experience in the pharmaceutical industry. Previously, he was associated with Concord Drugs Limited, Nectar Laboratories Private Limited and Vista Pharmaceuticals Limited. He is responsible for Company's production planning and oversees process development and production operations, product development, quality assurance and testing, regulatory inspections, and overall day-to-day operations.



Gurumoorthy Kamma
Head Corporate- Quality Assurance
Sai Parenteral's Limited

Gurumoorthy Kamma holds over 16 years' experience in the pharmaceutical industry. Prior to joining our Company, he was associated with Dr. Reddy's Laboratories Limited, Medreich Limited and Aurobindo Pharma Limited. He is responsible for overseeing the Company's quality assurance systems, compliance with regulatory standards, implementation of quality management processes, and ensuring product quality across all operations.



Anil Kumar
Chief Financial Officer
Sai Parenteral's Limited

Anil Kumar holds over 8 years of experience in finance. He was previously associated with Lauras Labs Private Limited and Neuland Laboratories Limited. He is responsible for the finance function at the company, including financial planning, budgeting, capital allocation and internal financial controls.



Shivali Aggarwal
Company Secretary and the Compliance Officer
Sai Parenteral's Limited


Shivali Aggarwal holds over 4 years' experience in the pharmaceutical industry, specializing in legal and secretarial functions. She is responsible for managing the Company's legal and secretarial affairs.



04

OUR
STRATEGY

1. Expansion into global injectable formulations market
2. Capitalize on CDMO opportunity by leveraging our commercial manufacturing with enhanced R&D competences
3. Strengthening our presence in regulated markets through the upcoming manufacturing facility at Adelaide, Australia
4. Focus on new product development to drive future growth
5. Grow our Branded Generic Formulations business by leveraging opportunities in the international markets



Usage of IPO proceeds

₹ **285** cr

IPO gross proceeds*

Particulars	Amount to be funded from net proceeds (₹ Cr)
Capacity expansion and upgradation of manufacturing facilities	111
Establishment of a new R&D Centre	18
Repayment / prepayment of certain outstanding institutional borrowings	14
Working capital requirements	33
Repayment of bridge and term loan in relation to the acquisition of Noumed Pharmaceuticals Pty Limited (Australia)	36
General corporate purposes	45
Issue expenses	28

* This figure includes general corporate purposes and offer related expenses

05


Annexure





Group Holding Company based in India

Houses branded generic formulations & CDMO products and services business



THANK YOU

For further information contact:
Investor relations
ir@saiparenterals.com

